The London Clinic is offering chimeric antigen receptor T-cell (CAR-T cell) therapy to adults with diffuse large B-cell lymphoma, where the patient’s immune cells are genetically modified to destroy their cancer cells.
The therapy works through the collection of immune cells (T cells) from the blood of patients. These T-cells are then genetically modified to destroy cancer cells in a laboratory and given back to the patient. This therapy is for patients who have no other treatment options having failed conventional chemotherapy.
A phase two clinical trial of 111 patients has shown positive outcomes with 52% of patients treated with CAR-T therapy living for 18 months after treatment. Real-world data is at an early stage but consistent with this positive outcome.
‘CAR-T cell therapy is an exciting advancement in the treatment of blood cancers, offering a new, final treatment option for patients when others haven’t had the result they need from conventional therapy,’ said Professor John Gribben, consultant at The London Clinic.
‘Diffuse large B-cell lymphoma is an aggressive form of blood cancer. So far, this treatment is showing promising outcomes for many patients, letting them return to normal lives with their families and loved-ones.’
Satya Bhattacharya, medical director of The London Clinic added: ‘The London Clinic is committed to bringing together it’s strengths in clinical service, research, and innovation to successfully deliver new treatments such as CAR-T cell therapy and create positive outcomes for our patients.’